Safety and Tolerability of SYNB1618 in Healthy Adult Volunteers and Adult Subjects With Phenylketonuria

NCT ID: NCT03516487

Last Updated: 2021-05-13

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 70 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-04-17
• Study Completion Date: 2019-06-21

Brief Summary

This Phase 1/2a, first-in-human, oral single and multiple dose-escalation, randomized, double-blinded, placebo-controlled study is evaluating SYNB1618 in healthy volunteers (HV) and subjects diagnosed with phenylketonuria (PKU), a rare inherited metabolic disorder that occurs in people who are missing an enzyme that the body needs to use phenylalanine (Phe). Eligible subjects receive investigational product (IP) in the clinic and undergo safety monitoring, evaluations, and subsequent follow-up after IP administration.

Detailed Description

This study is evaluating the safety, tolerability, kinetics, and pharmacodynamics of SYNB1618 within the following 2 study parts:

Part 1 comprises a single-ascending dose (SAD) study conducted over 4 days in HV male and female subjects in up to 6 dose cohorts (3 treated:1 placebo) to identify the maximum tolerated dose (MTD) within the single-dose range studied. Up to 24 HV subjects are planned for enrollment in this part of the study. Following attainment of the MTD in HV, a SAD cohort of up to 4 subjects (male and female, ≥ 18 years old) previously diagnosed with PKU will be enrolled (3 treated:1 placebo).

Part 2 comprises a multiple-ascending dose (MAD) study conducted in an inpatient setting (6 treated:2 placebo) over 10 days in HV male and female subjects in up to 4 cohorts at doses not exceeding the MTD from the SAD part of the study to identify the MTD of SYNB1618 within the multiple-dose range studied. Up to 32 HV subjects are planned for enrollment in this part of the study. Once the highest MAD cohort and the SAD PKU cohort are completed, a multiple-dose cohort of male and female subjects (≥ 18 years old) previously diagnosed with PKU are evaluated. Up to 20 subjects with PKU are planned for enrollment in the MAD PKU cohort (12 treated:8 placebo).

Conditions

Phenylketonuria; Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

SAD HV: SYNB1618 (1 x 10^10 CFU)

HV subjects receive a single oral dose of SYNB1618 (1 x 10\^10 colony-forming units \[CFU\]) in a chilled buffered solution on Day 1 in the SAD study (Part 1).

Group Type: EXPERIMENTAL

SYNB1618

Intervention Type: DRUG

SYNB1618 is supplied in a buffered solution in 5 mL polypropylene cryovials with a nominal 5 mL fill volume, administered with 100 mL of masking buffer solution.

SAD HV: SYNB1618 (5 x 10^10 CFU)

HV subjects receive a single oral dose of SYNB1618 (5 x 10\^10 CFU) in a chilled buffered solution on Day 1 in the SAD study (Part 1).

Group Type: EXPERIMENTAL

SYNB1618

Intervention Type: DRUG

SYNB1618 is supplied in a buffered solution in 5 mL polypropylene cryovials with a nominal 5 mL fill volume, administered with 100 mL of masking buffer solution.

SAD HV: SYNB1618 (1 x 10^11 CFU)

HV subjects receive a single oral dose of SYNB1618 (1 x 10\^11 CFU) in a chilled buffered solution on Day 1 in the SAD study (Part 1).

Group Type: EXPERIMENTAL

SYNB1618

Intervention Type: DRUG

SYNB1618 is supplied in a buffered solution in 5 mL polypropylene cryovials with a nominal 5 mL fill volume, administered with 100 mL of masking buffer solution.

SAD HV SB: SYNB1618 (1 x 10^11 CFU)

HV subjects receive a single oral dose of SYNB1618 (1 x 10\^11 CFU) in a chilled buffered solution on Day 1 in the SAD study (Part 1). On Day 1, subjects in this cohort receive a solid breakfast (SB) that contains approximately the same amount of calories and protein as the meal supplement shake given to subjects in the other SAD cohorts.

Group Type: EXPERIMENTAL

SYNB1618

Intervention Type: DRUG

SYNB1618 is supplied in a buffered solution in 5 mL polypropylene cryovials with a nominal 5 mL fill volume, administered with 100 mL of masking buffer solution.

SAD HV: SYNB1618 (2 x 10^11 CFU)

HV subjects receive a single oral dose of SYNB1618 (2 x 10\^11 CFU) in a chilled buffered solution on Day 1 in the SAD study (Part 1).

Group Type: EXPERIMENTAL

SYNB1618

Intervention Type: DRUG

SYNB1618 is supplied in a buffered solution in 5 mL polypropylene cryovials with a nominal 5 mL fill volume, administered with 100 mL of masking buffer solution.

SAD HV: SYNB1618 (5 x 10^11 CFU)

HV subjects receive a single oral dose of SYNB1618 (5 x 10\^11 CFU) in a chilled buffered solution on Day 1 in the SAD study (Part 1).

Group Type: EXPERIMENTAL

SYNB1618

Intervention Type: DRUG

SYNB1618 is supplied in a buffered solution in 5 mL polypropylene cryovials with a nominal 5 mL fill volume, administered with 100 mL of masking buffer solution.

SAD HV: Placebo

HV subjects receive a single oral dose of placebo in a chilled buffered solution on Day 1 in the SAD study (Part 1).

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Subjects receive placebo orally in a chilled buffered solution (100 mL).

SAD PKU: SYNB1618 (7 x 10^10 CFU)

Subjects with PKU receive a single oral dose of SYNB1618 (7 x 10\^10 CFU) in a chilled buffered solution on Day 1 in the SAD study (Part 1).

Group Type: EXPERIMENTAL

SYNB1618

Intervention Type: DRUG

SYNB1618 is supplied in a buffered solution in 5 mL polypropylene cryovials with a nominal 5 mL fill volume, administered with 100 mL of masking buffer solution.

SAD PKU: Placebo

HV subjects receive a single oral dose of placebo in a chilled buffered solution on Day 1 in the SAD study (Part 1).

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Subjects receive placebo orally in a chilled buffered solution (100 mL).

MAD HV: SYNB1618 (1 x 10^10 CFU)

HV subjects receive oral SYNB1618 (1 x 10\^10 CFU) in a chilled buffered solution 3 times per day (TID) for 7 days in the MAD study (Part 2).

Group Type: EXPERIMENTAL

SYNB1618

Intervention Type: DRUG

SYNB1618 is supplied in a buffered solution in 5 mL polypropylene cryovials with a nominal 5 mL fill volume, administered with 100 mL of masking buffer solution.

MAD HV: SYNB1618 (5 x 10^10 CFU)

HV subjects receive oral SYNB1618 (5 x 10\^10 CFU) in a chilled buffered solution TID for 7 days in the MAD study (Part 2).

Group Type: EXPERIMENTAL

SYNB1618

Intervention Type: DRUG

SYNB1618 is supplied in a buffered solution in 5 mL polypropylene cryovials with a nominal 5 mL fill volume, administered with 100 mL of masking buffer solution.

MAD HV: SYNB1618 (7 x 10^10 CFU)

HV subjects receive oral SYNB1618 (7 x 10\^10 CFU) in a chilled buffered solution TID for 7 days in the MAD study (Part 2).

Group Type: EXPERIMENTAL

SYNB1618

Intervention Type: DRUG

SYNB1618 is supplied in a buffered solution in 5 mL polypropylene cryovials with a nominal 5 mL fill volume, administered with 100 mL of masking buffer solution.

MAD HV: SYNB1618 (1 x 10^11 CFU)

HV subjects receive oral SYNB1618 (1 x 10\^11 CFU) in a chilled buffered solution TID for 7 days in the MAD study (Part 2).

Group Type: EXPERIMENTAL

SYNB1618

Intervention Type: DRUG

SYNB1618 is supplied in a buffered solution in 5 mL polypropylene cryovials with a nominal 5 mL fill volume, administered with 100 mL of masking buffer solution.

MAD HV: Placebo

HV subjects receive oral placebo in a chilled buffered solution TID for 7 days in the MAD study (Part 2).

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Subjects receive placebo orally in a chilled buffered solution (100 mL).

MAD PKU: SYNB1618 (7 x 10^10 CFU)

Subjects with PKU receive oral SYNB1618 (7 x 10\^10 CFU) in a chilled buffered solution TID for 7 days in the MAD study (Part 2).

Group Type: EXPERIMENTAL

SYNB1618

Intervention Type: DRUG

SYNB1618 is supplied in a buffered solution in 5 mL polypropylene cryovials with a nominal 5 mL fill volume, administered with 100 mL of masking buffer solution.

MAD PKU: Placebo

Subjects with PKU receive oral placebo in a chilled buffered solution TID for 7 days in the MAD study (Part 2).

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Subjects receive placebo orally in a chilled buffered solution (100 mL).

Interventions

SYNB1618

SYNB1618 is supplied in a buffered solution in 5 mL polypropylene cryovials with a nominal 5 mL fill volume, administered with 100 mL of masking buffer solution.

Intervention Type: DRUG

Placebo

Subjects receive placebo orally in a chilled buffered solution (100 mL).

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Age ≥ 18 to ≤ 64 years.

2. Able and willing to voluntarily complete the informed consent process (subject or subject's representative).

3. Available for and agrees to all study procedures, including feces, urine, and blood collection and adherence to diet control, inpatient monitoring, follow-up visits, and IP ingestion compliance.

4. Male subjects who are sexually abstinent or surgically sterilized (vasectomy), or those who are sexually active with a female partner(s) and agree to use an acceptable method of contraception (such as condom with spermicide) combined with an acceptable method of contraception for their non-pregnant female partner(s) (as defined in Inclusion Criterion #5) after informed consent, throughout the study, and for a minimum of 90 days after the last dose of IP, and who do not intend to donate sperm in the period from screening until 3 months following administration of the investigational medical product.

5. Female subjects that meet one of the following:

1. Women of childbearing potential must have a negative serum pregnancy test (human chorionic gonadotropin [HCG]) at screening and at baseline prior to the start of IP and must agree to use acceptable method(s) of contraception, combined with an acceptable method of contraception for their male partner(s) (as defined in Inclusion Criterion #4) after informed consent, throughout the study and for a minimum of 90 days after the last dose of IP. Acceptable methods of contraception include hormonal contraception, hormonal or non-hormonal intrauterine device, bilateral tubal occlusion, complete abstinence, vasectomized partner with documented azoospermia 90 days after procedure, diaphragm with spermicide, cervical cap with spermicide, vaginal sponge with spermicide, or male or female condom with or without spermicide.

2. Premenopausal woman with one of the following: i. Documented hysterectomy; ii. Documented bilateral salpingectomy; iii. Documented bilateral oophorectomy; iv. Documented tubal ligation/occlusion; v. Sexual abstinence is preferred or usual lifestyle of the subject.

3. Postmenopausal woman (12 months or more amenorrhea verified by follicle stimulating hormone assessment and over 45 years of age in the absence of other biological or physiological causes).

6. Screening laboratory evaluations (e.g., chemistry panel, complete blood count with differential, prothrombin time/activated partial thromboplastin time, urinalysis, C reactive protein, creatinine clearance) and electrocardiogram must be within normal limits or judged to be not clinically significant by the Investigator.

7. Stable diet including protein intake for at least 60 days prior to screening assessments.

8. Able to produce at least 2 bowel movements per week on average without the assistance of laxatives.

9. Diagnosis of classic PKU by either medical history of blood Phe concentration of >1200 µmol/L at any time OR genetic diagnosis.

10. Blood Phe concentration of ≥ 600 µmol/L at Screening.

11. Stable diet including stable medical formula regimen (if used) for 60 days prior to screening assessments.

Exclusion Criteria

1. Acute or chronic medical, surgical, psychiatric, or social condition or laboratory abnormality that may increase subject risk associated with study participation, compromise adherence to study procedures and requirements, or confound interpretation of study safety or pharmacodynamic results and, in the judgment of the Investigator, make the subject inappropriate for enrollment.

2. Body mass index < 18.5 or ≥ 30 kg/m^2 (> 40 kg/m^2 for PKU subjects).

3. History of or current immunodeficiency disorder including autoimmune disorders and human immunodeficiency virus antibody positivity.

4. Hepatitis B surface antigen positivity (subjects with hepatitis B surface antibody positivity and hepatitis B core antibody positivity are not excluded, provided that the hepatitis B surface antigen is negative).

5. Hepatitis C antibody positivity, unless a hepatitis C virus ribonucleic acid test is performed and the result is negative.

6. History of febrile illness, confirmed bacteremia, or other active infection within 30 days prior to the anticipated first dose of IP.

7. History of active or chronic passage of 3 or more loose stools per day.

8. Active laxative use within 30 days prior to the anticipated first dose of IP.

9. Active inflammatory or irritable bowel disorder of any grade.

10. Active or past history of gastrointestinal bleeding within 60 days prior to the Screening Visit as confirmed via hospitalization-related event(s) or medical history of hematemesis or hematochezia.

11. Intolerance of or allergic reaction to E. coli Nissle or any of the ingredients in SYNB1618 or placebo formulations.

12. Any condition, prescription medication, or over-the-counter product that may possibly affect absorption of medications or nutrients (e.g., celiac disease, gastrectomy, bypass surgery, ileostomy).

13. Currently taking or plans to take any type of systemic (e.g., oral or intravenous) antibiotic within 28 days prior to the anticipated first dose of IP through the final outpatient follow-up. Exception: topical antibiotics are allowed.

14. Major surgery (an operation upon an organ within the cranium, chest, abdomen, or pelvic cavity) or inpatient hospital stay within the 3 months prior to the anticipated first dose of IP.

15. Planned surgery, hospitalizations, dental, or interventional studies between screening and last anticipated visit that might require antibiotics.

16. Taking or planning to take probiotic supplements (enriched foods excluded) within 28 days prior to the anticipated first dose of IP and for the duration of participation and follow-up.

17. Dependence on drugs of abuse.

18. Regular alcohol consumption in excess of 14 standard drinks/week for men and in excess of 7 standard drinks/week for women and/or any evidence of binge or heavy drinking (according to National Institute on Alcohol Abuse and Alcoholism guidelines). One drink is equivalent to 12 g of alcohol: 12 oz (360 mL) of beer, 5 oz (150 mL) of wine or 1.5 oz (45 mL) of 80 proof distilled spirits.

19. Administration or ingestion of an investigational drug within 60 days or 5 half-lives, whichever is longer, prior to the Screening Visit or current enrollment in an investigational study. (PKU subjects who participate in the PKU SAD cohort may be eligible for screening for the PKU MAD cohort ≥ 30 days after the last dose of IP.)

20. Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular (including stable coronary artery disease/angina or prior cardiac stent), hepatic, neurologic, or allergic disease including drug allergies.

21. Screening laboratory parameters within the acceptable range.

22. Currently taking (within 1 week prior to screening) sapropterin (KUVAN®).

23. Currently taking (within 6 months prior to screening) pegylated recombinant phenylalanine ammonia lyase (PALYNZIQ™).

24. History of a severe immune reaction based on National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) after administration of pegylated recombinant phenylalanine ammonia lyase (PALYNZIQ).

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 64 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Synlogic

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Boston Children's Hospital

Boston, Massachusetts, United States

Children's Hospital of Pittsburgh of UPMC

Pittsburgh, Pennsylvania, United States

Vanderbilt University Medical Center

Nashville, Tennessee, United States

PRA Health Sciences

Salt Lake City, Utah, United States

Countries

United States

References

Puurunen MK, Vockley J, Searle SL, Sacharow SJ, Phillips JA 3rd, Denney WS, Goodlett BD, Wagner DA, Blankstein L, Castillo MJ, Charbonneau MR, Isabella VM, Sethuraman VV, Riese RJ, Kurtz CB, Brennan AM. Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a study. Nat Metab. 2021 Aug;3(8):1125-1132. doi: 10.1038/s42255-021-00430-7. Epub 2021 Jul 22.

Reference Type: DERIVED

PMID: 34294923 (View on PubMed)

Charbonneau MR, Denney WS, Horvath NG, Cantarella P, Castillo MJ, Puurunen MK, Brennan AM. Development of a mechanistic model to predict synthetic biotic activity in healthy volunteers and patients with phenylketonuria. Commun Biol. 2021 Jul 22;4(1):898. doi: 10.1038/s42003-021-02183-1.

Reference Type: DERIVED

PMID: 34294862 (View on PubMed)

Other Identifiers

SYNB1618-CP-001

Identifier Type: -

Identifier Source: org_study_id